Book a Meeting

Anti-CD27 Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP576) (CAT#: AES-0622-ZP576) Datasheet

Target
CD27
Description
Anti-CD27 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD27 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD27 Molecule
Background
Varlilumab; CD27; CD27 molecule; TNFRSF7; tumor necrosis factor receptor superfamily; member 7; CD27 antigen; S152; Tp55; CD27L receptor; T cell activation antigen S152; T-cell activation antigen CD27; tumor necrosis factor receptor superfamily; member 7; T14;
Antibody Clone
AES-0622-ZP576
Description
Anti-CD27 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.